CCRM Au and BioCurate enter into an MoU to accelerate the translation of therapies in the Australian regenerative medicine sector

Green molecular image

The Centre for Commercialization of Regenerative Medicine Australia and BioCurate enter into a Memorandum of Understanding (MoU) to accelerate the translation of therapies in the Australian regenerative medicine sector.

The Centre for Commercialization of Regenerative Medicine Australia (CCRM Australia) is proud to collaborate with BioCurate to advance the translation and commercialisation of life changing therapies in the Australian regenerative medicine sector.

Australia has a vibrant and world-class regenerative medicine eco-system and is internationally recognised for its discovery and translational research.  However, the developmental path of promising regenerative medicines is often fragmented, opportunistic and ad hoc. The commercially relevant skill set and dedicated financial capital of CCRM and BioCurate are critical resources available to assist researchers and startups navigate this challenging development path.

This MoU lays the foundation for collaboration between CCRM Australia and BioCurate. The scope promotes identification of suitable projects that parties can contribute towards by leveraging their expertise, networks and financial resources with the goal of joint translation of regenerative medicine in its broadest definition, i.e. harness the power of cellular and gene therapies to treat, repair, regenerate or replace diseased cells, tissues and organs, and to cure diseases. Where appropriate, both CCRM Australia and BioCurate will support each other’s programmes to train the next wave of entrepreneurs on the business of regenerative medicine.

CCRM Australia’s CEO Silvio Tiziani noted, “CCRM Australia is thrilled to be working with the BioCurate team to support Australia’s growing regenerative medicine industry.  It is clear that the development of regenerative medicine has come of age and with many therapies currently in and coming out of clinical trials, it is critical for Australia to translate its strong research pipeline and add to this new wave of life changing therapies.”

BioCurate’s CEO Dr Glenn Begley stated, “The boundary of medicines has yet again shifted beyond pharmaceutical drugs and biologics to include cellular therapies and gene therapies. Furthermore, the meteoric rise of CAR-T cancer immunotherapies has inevitably attracted clinical as well as investment interests. BioCurate’s collaboration with CCRM Australia is a critical step to accelerate the translation of innovative regenerative medicine research into the healthcare market.”

The signing of the MoU brings together leaders in drug, biologic, regenerative medicine and medical technology development to pave a viable translation and commercialisation pathway for the Australian regenerative medicine sector.

About CCRM Australia: ccrmaustralia.com.au

CCRM Australia is an Australian not-for-profit organisation supporting the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies. CCRM Australia’s focus is to bridge the commercialisation gap through a network of scientists, entrepreneurs, academic institutions and industry partners and address bottlenecks in the industry. CCRM Australia is modelled on the highly successful CCRM in Canada and is legally separate to CCRM. As a member of the Global CCRM network, CCRM Australia is a partner to a leading-edge industry consortium. CCRM Australia is supported by MTPConnect and the Victorian State Government.

Subscribe to the CCRM Australia newsletter: Click here

Twitter: @ccrm_au

LinkedIn: https://www.linkedin.com/company/ccrm-australia/

About BioCurate: www.biocurate.com

BioCurate Pty Ltd was formed jointly in June 2016 by The University of Melbourne and Monash University, with support from the Victorian State Government to accelerate early phases of new drug development. BioCurate is seeking to address the key challenges in early stage drug development and to increase the number, quality and rate of translation of new drug discoveries into medically sound projects that are attractive for investment via commercial or public-good routes. The Company’s vision is to be a recognized global leader in the translation of basic medical research into human therapeutics. For more information, please visit http://www.biocurate.com.

Twitter: @biocurate

LinkedIn: https://www.linkedin.com/company/biocurate/

For more information, please contact:

CCRM Australia: Dr Chih Wei Teng                           chihwei.teng@ccrmaustralia.com.au

BioCurate: Dr Damien Bates                                      d.bates@biocurate.com

BioCurate and CCRM logos